International Edition
Latest News
Health

US Researchers Break Pancreatic Cancer Shield, Tumors Shrink 75%

On November 15, 2026, scientific reports indicated that half of all patients discover their pancreatic cancer is already metastasized, according to Science et vie. The 5-year survival rate for the disease remains at 11 percent, as noted by…

US Researchers Break Pancreatic Cancer Shield, Tumors Shrink 75%

On November 15, 2026, scientific reports indicated that half of all patients discover their pancreatic cancer is already metastasized, according to Science et vie.

The 5-year survival rate for the disease remains at 11 percent, as noted by the Robert Koch Institute’s Cancer Registry and cited by Science et vie. For comparison, the 5-year survival rate reaches 92 percent for prostate cancer, as reported by Science et vie.

Pr Jens Werner, president of the German Society for Surgery, said that tumors often progress silently in the abdomen before symptoms appear. Common warning signs include abdominal pain, weight loss, jaunisse, itching, nausea, and sudden onset type 2 diabetes.

Sudden type 2 diabetes in an individual without known risk factors constitutes the sixth signal, as the gland produces insulin to regulate blood sugar, and a tumor can disrupt this mechanism, sometimes causing diabetes to appear before any pain, according to Science et vie.

Medical guidance recommends consulting a physician when these symptoms persist for two to four weeks.

In France, approximately 16,000 new cases are diagnosed annually, resulting in more than 11,000 deaths each year, according to figures from Public Health France and the National Cancer Institute reported by Medisite.fr. Only 10 percent to 20 percent of patients present with an operable lesion at the time of diagnosis.

To address diagnostic delays, the Reims University Hospital launched its “Urgence Tumeur Pancréas” pathway on November 19, 2026, coinciding with World Pancreatic Cancer Day. The dedicated pathway ensures specialized consultations within 48 hours for patients with suspected pancreatic lesions, aiming for personalized treatment plans within 15 days, as reported by the CHU de Reims.

Solid tumors, including those in the pancreas, protect themselves with a dense scar-like tissue barrier that blocks immune system T cells, according to findings published in Cancer Cell and reported by Ma Clinique and Medisite.fr. Researchers in the United States and South Korea tested an experimental molecule designed to break this protective armor from within. To orchestrate this fibrous shielding and paralyze immunity, the tumor secretes in abundance a signaling molecule named TGF-β, as reported by Medisite.fr.

In laboratory models, the treatment allowed CD8+ killer T cells to penetrate the tumor and destroy 75 percent of pancreatic tumors, according to Medisite.fr.

Deprived of its collagen rampart, the tumor finds itself invaded by CD8+ T lymphocytes, which release interferon gamma and force the cellular environment to unmask the cancer, as reported by Medisite.fr. Survival data confirm this efficacy, with 87.5 percent of animals still alive 270 days after the total cessation of injections, according to Medisite.fr.

“We seem to teach the immune system lessons it remembers long after the tumor has gone, and in some cases, these lessons protect against other cancers,” researchers noted, as reported by Medisite.fr.

Human clinical evaluations for patients with solid tumors resistant to standard therapies are scheduled to begin by 2027, according to Medisite.fr.

About the author: Dr Natalie Singh - Health Editor

Board‑certified internal‑medicine physician and MPH. Natalie authored peer‑reviewed studies on infectious disease and served as medical editor. “Dr. Natalie Singh delivers evidence‑based health news, medical breakthroughs, and expert wellness guidance.”